معرفی
Mara Artibani is a Lecturer in Biology at Jesus College, University of Oxford, and a Senior Postdoc in the Ovarian Cancer Cell Laboratory. Her research focuses on improving ovarian cancer outcomes by targeting metabolic vulnerabilities in Minimal Residual Disease (MRD) and identifying non-invasive biomarkers for early detection.
She uses single-cell RNA sequencing to characterize genomic and transcriptomic subtypes of fallopian tube epithelial cells, the origin of serous ovarian cancer. Her work demonstrates how non-genetic heterogeneity (NGH) drives tumor resilience and poor prognosis, particularly in EMT-high subtypes. Key findings include cell-state transitions in high-grade serous ovarian cancer (HGSOC) and validation of KRT17-positive secretory cell subtypes with immunofluorescence markers.
Her publications reveal trends in EMT-based risk stratification and cell-state deconvolution of 1,700+ tumors. These studies highlight Wnt signaling perturbations, stromal interactions, and non-genetic tumor heterogeneity as critical for therapeutic strategies.
She has contributed to Cell, Cancer Cell, and Clinical Cancer Research, emphasizing the need to refine prognostic classifications by integrating cell-of-origin biology with transcriptomic signatures.
Her laboratory work includes organoid culture systems and Laser Capture Microdissection (LCM) to validate EMT-high tumor subtypes through SPARC and HLA-DR expression. This approach has identified 12 marker genes for robust tumor stratification, now being tested in OXO-PCR cohort studies.
